Bibliographys
- MORIS G, GARCIA-MONCO JC: The challenge of drug-induced aseptic meningitis. Arch. Intern. Med. (1999) 159(11):1185–1194.
- • A good discussion paper on aseptic meningitis.
- WASNER CK: Ibuprofen, meningitis, and systemic lupus erythematosus. .1 Rheumatol (1978) 5(2):162–164.
- SAMUELSON CO, WILLIAMS HJ: Ibuprofen-associated aseptic meningitis in systemic lupus erythematosus. West. J. Med. (1979) 131(1):57–59.
- BERLINER S, WEINBERGER A, SHOENFELD Y et al: Ibuprofen may induce meningitis in (NZB X NZW)F1 mice. Arthritis Rheum. (1985) 28(1):104–107.
- RUPPERT GB, BARTH WF: Tolmetin-induced aseptic meningitis. JAMA (1981) 245(1):67–68.
- WEKSLER BB, LEHANY AM: Naproxen-induced recurrent aseptic meningitis. DICP (1991) 25(11):1183–1184.
- BALLAS ZK, DONTA ST: Sulindac-induced aseptic meningitis. Arch. Intern. Med. (1982) 142(1):165–166.
- SHOENFELD Y, LIVNI E, SHAKLAI M et al.: Sensitization to ibuprofen in systemic lupus erythematosus. JAMA (1980) 244(6):547–548.
- NO AUTHORS LISTED: Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italian° Studi Epidemiologici in Dermatologia. Dermatology (1993) 186(3):164–169.
- •A thorough review of cutaneous reactions to NSAIDs.
- SZCZEKLIK A, GRYGLEWSKI RJ, CZERNIAWSKA-MYSIK G: Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs andtheir pathogenesis. I Allergy Clin. Immunol (1977) 60(5):276–284.
- BIGBY M, STERN R: Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. Am. Acad. Dermatol (1985) 12(5):866–876.
- PETRI M, ALLBRITTON J: Antibiotic allergy in systemic lupus erythematosus: a case-control study. Rheumatol (1992) 19(2):265–269.
- WANG CR, CHUANG CY, CHEN CY: Drug allergy in Chinese patients with systemic lupus erythematosus. Rheumatol (1993) 20(2):399–400.
- DESHAZO RD, KEMP SF: Allergic reactions to drugs and biologic agents. JAMA (1997) 278(22):1895–1906.
- PATTERSON R, BELLO AE, LEFKOWITH J: Immunologic tolerability profile of celecoxib. Clin. Ther. (1999) 21(12):2065–2079.
- CHIOLERO A, MAILLARD MP, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Sal (2002) 1(1):45–52.
- •A good discussion paper on the cardiovascular profile of COX-2 inhibitors.
- MEAGHER EA: Balancing gastroprotection and cardioprotection with selective cyclooxygenase 2 inhibitors: clinical implications. Drug Sat: (2003) 26(13):913–924.
- •A good discussion paper on the cardiovascular profile of COX-2 inhibitors.
- NISHIHARA KK, FURST DE: Aspirin and other nonsteroidal anti-inflammatory drugs. In: Arthritis and allied conditions: a textbook on rheumatology. Williams & Wilkins, Baltimore (1997):611–654.
- MAICHE AG: Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet (1986) 1(8494):1390.
- STEWART CF: Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. (1991) 34(12):1514–1520.
- MACONES GA, MARDER SJ, CLOTHIER B et al.: The controversy surrounding indomethacin for tocolysis. Am.j Obstet. Cynecol (2001) 184:264–272.
- BARRY WS, MEINZINGER MM, HOWSE CR: Ibuprofen overdose and exposure in utero: results from a postmarketing voluntary reporting system. Am. Med. (1984) 77:35–39.
- LID, LIU L, ODOULI R: Exposure to nonsteroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br. Med. J. (2003) 327:368–372.
- •NSAID risk for miscarriages, a cohort study.
- NIELSEN GL, SORENSEN HT, LARSEN H et al: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population-based observational study and case-control study. Br. Med. (2001) 322:266–270.
- •NSAID risk for miscarriages, a case-control study.
- NO AUTHORS LISTED: CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet (1994) 343:619–629.